Louise Bønnelykke-Behrndtz awarded grant from the Neye Foundation

ACROBATIC member, Louise Bønnelykke-Behrndtz, has been awarded a grant from the Neye Foundation to support the PRIME project: “Peri-operative treatment with tranexamic acid (TXA); prognostic and treatment related impact of the plasmin(ogen) pathway in melanoma”.

In recent years, treatment of cancer prevention with well-known and well-tested drugs has gained traction. As a completely new approach, the PRIME project proposes that the well-known and well-tested substance, Tranexamic acid, which reduces the risk of bleeding, can also be used for prevention against recurrence after surgery for patients with mole cancer. This is based on recent research that suggests that tranexamic acid affects the immune system in a expedient manner and reduces the ability of cancer cells to divide and spread.

The purpose of the studies is to conduct a random trial and test whether treatment with tranexamic acid can reduce the number of relapses and the risk of complications after surgery in comparison to placebo. At the same time, we will analyze blood and tissue samples, and carry out basic animal experiments, in order to understand the prognostic and treatment consequences surgery and tranexamic acid can have for the patients.

The generous grant from the NEYE foundation enables PRIME project to carry out the studies mentioned above. The project is expected to contribute to the optimization of surgical treatment and improving the prognosis for patients with birthmark cancer.